Advanced Therapies Integrates 2022 Track 2
TECH TO TRANSLATE
Discover the scientific and technological innovations to support your ATMP getting to market.
Welcome and opening remarks
MATTHEW DURDY | Chief Executive Officer | Cell and Gene Therapy Catapult
Fireside Chat
An interview with:
MARTIN MURPHY | Chief Executive Officer | Syncona Investment Management Limited
Interviewed by:
MATTHEW DURDY | Chief Executive Officer | Cell and Gene Therapy Catapult
Fireside Chat
An interview with:
NICOLA REDFERN | Consultant | NJ Redfern Ltd
Interviewed by:
MATTHEW DURDY | Chief Executive Officer | Cell and Gene Therapy Catapult
Advancing through the clinic to market
What do you need to consider to progress advanced therapies through the clinical phase of development?
FACILITATED BY
Flic Gabbay | Founding & Senior Partner | tranScrip
PANELLISTS
William Scott | Scientific Director, Transplant Regenerative Medicine | Newcastle University Medical School
Miguel Forte | Chief Executive Officer | Bone Therapeutics
Agathe Guillot | Senior Regulatory Consultant | DLRC
Jimmy McBlane | Preclinical Assessor | MHRA
Raja Sharif | Founder and Chief Executive Officer | ATMPS Ltd
Prepare for patients
Identifying the best targets, using AI, BioInformatics and ‘Omics’ approaches to improve biological understanding and predict efficacy and pharmacology for cell and gene therapies.
What should you consider when getting an advanced therapy ready for First in Human trials? Does it have the 5Rs: right target, right tissue, right safety, right patient and right commercial potential?
FACILITATED BY
Terri Gaskell | Chief Technical Officer | Rinri Therapeutics Ltd
PANELLISTS
Lee Coney | Head of Non-Clinical Safety | Cell and Gene Therapy Catapult
Mustafa Munye | Director of R&D Operations | Complement Therapeutics
Jimmy McBlane | Preclinical Assessor | MHRA
Neelam Panchal | Senior Commercialisation of Research Scientist | Cell and Gene Therapy Catapult
Fraser McBlane | Global Project Team Lead for Pharmacokinetic Sciences | Novartis